Results 171 to 180 of about 163,674 (312)

Defective high‐density lipoprotein lipoprotection in type 2 diabetes during acute myocardial infarction is rescued by apolipoprotein M/sphingosine‐1‐phosphate loading

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Mortality of patients with type 2 diabetes (T2D) after acute myocardial infarction (AMI) is tremendous and massively increased compared to non‐T2D individuals. The reasons are unclear. High‐density lipoprotein (HDL) conducts lipoprotection during AMI, leading to improved outcomes.
Jens Vogt, Marcel Benkhoff, Nathalie H. Schröder, Hao Hu, Lisa Dannenberg, Petra Keul, Theresia Sarabhai, Kálmán Benedikt Bódis, Tobias Zeus, Philipp Wollnitzke, Malte Kelm, Amin Polzin, Bodo Levkau   +12 more
wiley   +1 more source

Septic Myocarditis Masquerading as Acute Inferior ST-Elevation Myocardial Infarction. [PDF]

Cureus
Lahiri S, Rashid O, Goel A, Moondhra A.
europepmc   +1 more source

Sex differences in trial representation and the cardiovascular effectiveness of newer glucose‐lowering agents in patients with and without type 2 diabetes: A systematic review and meta‐analysis of cardiovascular outcome trials

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The extent to which the cardiovascular benefits of sodium–glucose co‐transporter 2 inhibitors (SGLT‐2is) and glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) differ by sex remains unclear. This systematic meta‐analysis aimed to investigate sex differences in trial representation and the cardiovascular and kidney efficacy of SGLT‐2is ...
Magdaline Zawadka, Erwin Taguiam, Mê‐Linh Lê, Rohan Sanjanwala, Shuangbo Liu, Ashish H. Shah, Setor K. Kunutsor   +6 more
wiley   +1 more source

Pseudo-Anterior ST-Elevation Myocardial Infarction Due to Hypertrophic Cardiomyopathy. [PDF]

Cureus
Lekwa C, Thahakutty AH, Ahmad S, Attar N.   +3 more
europepmc   +1 more source

An oral glucose tolerance test in pregnancy and its association with future cardiovascular diseases

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims/hypothesis Gestational diabetes and abnormal 100‐g oral glucose tolerance test (OGTT) results in pregnancy are associated with type 2 diabetes, but their relationship with cardiovascular disease (CVD) is less clear. We evaluated the risk of CVD according to the number of abnormal OGTT values during pregnancy.
Tal Schiller, Linoy Gabay, Oren Barak, Alena Kirzhner, Haitham Abu Khadija, Gabriel Chodick, Edi Vaisbuch, Yael Barer   +7 more
wiley   +1 more source

Long-term all-cause mortality rate after ST-elevation myocardial infarction and its predictors: ST Elevation Myocardial Infarction Cohort in Isfahan Study. [PDF]

J Res Med Sci
Shojaei Y, Sadeghi M, Mehrabani K, Sadri M, Rouhani S, Hassannejad R, Roohafza H.   +6 more
europepmc   +1 more source

Hypoxia regulates Th17/Treg balance by altering chromatin accessibility and gene expression

The FEBS Journal, EarlyView.
T‐cell differentiation into Th17 or iTreg cells is key to inflammation control. Integrated RNA‐seq and ATAC‐seq analyses reveal that hypoxia induces more extensive gene expression changes in iTreg cells. Elevated levels of Hif1a and Stat3, along with increased accessibility to key transcription factor motifs, may predispose these cells toward ...
Mariana Cázares‐Olivera, Shiyang Song, Sofia Ylinen, Talha Qureshi, Bin Li, Zhi Chen   +5 more
wiley   +1 more source

Transfer and Survival of ST-Elevation Myocardial Infarction Medicare Patients. [PDF]

Cardiol Res
Leeberg M, Shermeyer A, Ward MJ, Virnig B, Wolfson J, Carroll C, Nikpay S.   +6 more
europepmc   +1 more source

DEXMEDETOMIDINE WITHDRAWAL MIMICKING ST-ELEVATION MYOCARDIAL INFARCTION

Journal of the American College of Cardiology, 2023
Lakra, Pallavi, Rao, Shiavax J., Dangol, Raj K., Saleh, Nahar   +3 more
openaire   +2 more sources

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the safety, tolerability, and treatment effects of rimegepant 75 mg every other calendar day (EOD) for the preventive treatment of migraine in a 52‐week, open‐label extension (OLE) study. Background Rimegepant is an oral small molecule calcitonin gene–related peptide receptor antagonist approved for the acute treatment of ...
David Kudrow, Robert S. Croop, Alexandra Thiry, Richard B. Lipton   +3 more
wiley   +1 more source